GCC pharmaceutical market forecast to exceed $10 billion by 2020

11 April 2013

The Gulf Cooperation Council (GCC)’s market for European-made drugs and medicines is expected to pass $10 billion by 2020, according to a new report by QNB Capital, reported by Gulf Business News.

The news comes as Spanish drug manufacturer, Laboratorios Cinfa, launched in the region this week, opening its services to the United Arab Emirates (UAE) market. “Our experience, our scientists team and our cutting edge technology have enabled us to lead the Spanish market and to be present in more than 50 countries worldwide,” said Enrique Ordieres, president of Cinfa.

“Cinfa is now arriving in the United Arab Emirates, an advanced society demanding the highest quality standards. Our aim is to contribute to society’s well-being by providing high quality drugs, with the guarantee of a world class European laboratory,” he added.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK